Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece
07 déc. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that,...
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra
06 déc. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
22 nov. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with ARDS Received authorization to expand ongoing sepsis and...
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
10 nov. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain
04 nov. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine
12 oct. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Publication follows the Israeli Ministry of Health’s appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines Nes-Ziona, Israel, Oct. 12,...
Enlivex Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells
05 oct. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis
04 oct. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...
Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021
29 sept. 2021 08h48 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS
22 sept. 2021 06h00 HE
|
Enlivex Therapeutics Ltd
Top-line data from the randomized, multi-center trial are expected in Q2-2022 Nes-Ziona, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a...